Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.032
Sell
RSI(14)
26.998
Sell
STOCH(KDJ)(9,3,3)
19.013
Neutral
ATR(14)
0.057
High Vlolatility
CCI(14)
-124.549
Sell
Williams %R
78.841
Sell
TRIX(12,20)
-1.011
Sell
StochRSI(14)
87.347
Buy
Talphera Inc
TLPH0.814USD
+0.025+3.21%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
37.12MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Talphera Inc
Currency: USD Updated: 2026-02-06Key Insights
Talphera Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 107 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.25.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Talphera Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Talphera Inc Highlights
StrengthsRisks
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Undervalued
The company’s latest PE is -2.15, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 18.49M shares, increasing 32.12% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 50.21K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 12.05.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.250
Target Price
+311.97%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Talphera Inc is 5.45, ranking 158 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is low.
Score
Financials
5.35
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.07
Operational Efficiency
2.83
Growth Potential
4.92
Shareholder Returns
7.07
Talphera Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Talphera Inc is 6.97, ranking 105 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -2.15, which is -120.99% below the recent high of 0.45 and -79.32% above the recent low of -3.86.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 107/159
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Talphera Inc is 8.00, ranking 57 out of 159 in the Pharmaceuticals industry. The average price target is 3.50, with a high of 6.00 and a low of 3.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
3.250
Target Price
+311.97%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
173
Total
6
Median
8
Average
Company name
Ratings
Analysts
Talphera Inc
TLPH
2
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Eli Lilly and Co
LLY
33
Vertex Pharmaceuticals Inc
VRTX
33
Gilead Sciences Inc
GILD
31
1
2
3
...
35
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Talphera Inc is 6.48, ranking 125 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.06 and the support level at 0.66, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
0.830
Sell
MA10
0.907
Sell
MA20
0.962
Sell
MA50
1.099
Sell
MA100
1.124
Sell
MA200
0.814
Buy
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Talphera Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 39.67%, representing a quarter-over-quarter increase of 27.53%. The largest institutional shareholder is The Vanguard, holding a total of 663.68K shares, representing 1.42% of shares outstanding, with 2.50% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
CorMedix Inc
Rosalind Advisors, Inc.
Lytton (Laurence W)
Rock Springs Capital Management LP
Nantahala Capital Management, LLC
AIGH Capital Management, LLC.
Worth Venture Partners, LLC
Bleichroeder LP
Angotti Vincent J
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Talphera Inc is 2.24, ranking 132 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.49. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Talphera Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
0.49
VaR
+8.69%
240-Day Maximum Drawdown
+45.97%
240-Day Volatility
+131.77%
Return
Best Daily Return
60 days
+19.05%
120 days
+49.13%
5 years
+49.13%
Worst Daily Return
60 days
-18.60%
120 days
-18.60%
5 years
-25.61%
Sharpe Ratio
60 days
-1.64
120 days
+1.68
5 years
-0.27
Risk Assessment
Maximum Drawdown
240 days
+45.97%
3 years
+73.37%
5 years
+98.83%
Return-to-Drawdown Ratio
240 days
+1.09
3 years
+0.07
5 years
-0.20
Skewness
240 days
+2.57
3 years
+1.47
5 years
+1.34
Volatility
Realised Volatility
240 days
+131.77%
5 years
+121.31%
Standardised True Range
240 days
+8.99%
5 years
+46.41%
Downside Risk-Adjusted Return
120 days
+335.67%
240 days
+335.67%
Maximum Daily Upside Volatility
60 days
+73.49%
Maximum Daily Downside Volatility
60 days
+65.68%
Liquidity
Average Turnover Rate
60 days
+10.24%
120 days
+5.29%
5 years
--
Turnover Deviation
20 days
+1205.33%
60 days
+481.70%
120 days
+200.49%
Peer Comparison
Pharmaceuticals
Talphera Inc
TLPH
5.83 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mckesson Corp
MCK
9.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.92 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
UTHR
8.86 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.72 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.70 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
